Chitosan oligosaccharide
Based on 5 publication(s) in Google Scholar
Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.
For research use only. We do not sell to patients.
- Purity : 91.0%
- CAS No.: 148411-57-8
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-17364
TemozolomideDNA Alkylator -
HY-126389
Chitin, from crab carapace (powder),biomedical research gradeBiochemical Assay Reagent -
HY-50662
A-769662AMPK Activator -
HY-112233
O-304AMPK Activator -
HY-N6631
7-MethoxyisoflavoneAMPK Activator -
HY-12831
AmpkinoneAMPK Activator -
HY-112769
EX229AMPK Activator -
HY-12357
Bempedoic acidACL Inhibitor/AMPK Activator -
HY-103683
PF-06409577AMPK Activator -
HY-100548
GSK621AMPK Activator -
HY-P0136
SAMSAMPK Substrate -
HY-N1411
Platycodin DAMPK Activator
Publications Citing Use of MedChemExpress (MCE) Chitosan oligosaccharide
MoreAll AMPK Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
AMPK[1]
In Vitro
Chitosan oligosaccharide (COS) represents a class of natural polymers that holds therapeutic promise in several diseases due to not only its physiochemical properties including water-solubility and low viscosity but also its favorable pharmacological properties including good pharmacokinetics and safety profiles and diverse beneficial biological activities. Activation of AMPK and inhibition of inflammatory signaling pathways including NF-κB and MAPK pathways are recognized as major mechanisms responsible for several effects of Chitosan oligosaccharide (COS) including anti-inflammation, anti-cancer, and anti-diabetes. COS can interrupt cancer progression at multiple stages by modulating several signaling proteins/pathways including NF-κB, AMPK, mTOR, caspase-3, CD147, MMP-2, MMP-9, and VEGF. In vitro experiments have demonstrated that Chitosan oligosaccharide (COS) induced the death of several cancer cell types including ascites, bladder cancer, prostate cancer, lung cancer, liver cancer, leukemia, cervical cancer and colorectal cancer. The values of IC50 of Chitosan oligosaccharide (COS) in inducing cytotoxicity are 25 μg/mL-50 μg/mL depending on types of cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 148411-57-8
-
Appearance Solid
-
Color Light yellow to yellow
-
SMILES
[Chitosan oligosaccharide]
-
Synonyms
COS
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
An Apple Susceptibility-Related LRR Receptor-Like Kinase MdRLKT21 Activates Plant Immunity by Hijacking a Trans-Kingdom Fungal microRNA-Like RNA. [Abstract]2025 Aug 4:e17426. PMID: 40755370 -
Acta Pharmacol Sin
Pretreatment with chitosan oligosaccharides attenuate experimental severe acute pancreatitis via inhibiting oxidative stress and modulating intestinal homeostasis. [Abstract]2021 Jun;42(6):942-953. PMID: 33495520 -
Nutrients
2022 Nov 7;14(21):4699. PMID: 36364961 -
J Biomed Mater Res A
Macrophage polarization in vitro and in vivo modified by contact with fragmented chitosan hydrogel. [Abstract]2022 Apr;110(4):773-787. PMID: 34723433 -
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (Need ultrasonic)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL; Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Muanprasat C, et al. Chitosan oligosaccharide: Biological activities and potential therapeutic applications. Pharmacol Ther. 2017 Feb;170:80-97 [Content Brief]
[2]. Kong SZ, et al. Anti-photoaging effects of chitosan oligosaccharide in ultraviolet-irradiated hairless mouse skin. Exp Gerontol. 2018 Mar;103:27-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Chitosan oligosaccharide Related Classifications
HY-112108 Related Classifications
Powered by Bioz